Pharmacyte Biotech Stock In The News
| PMCB Stock | USD 2.20 0.07 3.29% |
The tone or emotional content of news articles related to PharmaCyte Biotech can affect its prices. Positive news sentiment can lead to an increase in demand for PharmaCyte Biotech's stock, while negative news sentiment can lead to a decrease in demand. Our overall analysis of PharmaCyte Biotech's news coverage and content from conventional and social sources shows investors' bearish mood towards PharmaCyte Biotech. The specific impact of PharmaCyte Biotech news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of PharmaCyte Biotech's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using PharmaCyte Biotech headlines in addition to utilizing other, more conventional financial analysis modules. Check out PharmaCyte Biotech Backtesting and PharmaCyte Biotech Hype Analysis. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.
PharmaCyte |
PharmaCyte Biotech Today Top News and Investor Outlook
PharmaCyte Biotech Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide PharmaCyte and other traded companies coverage. We help investors stay connected with PharmaCyte headlines for the 25th of April to make an informed investment decision based on correlating the impacts of news items on PharmaCyte Stock performance. Please note that trading solely based on the PharmaCyte Biotech hype is not for everyone as timely availability and quick action are needed to avoid losses.PharmaCyte Biotech stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the PharmaCyte earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about PharmaCyte Biotech that are available to investors today. That information is available publicly through PharmaCyte media outlets and privately through word of mouth or via PharmaCyte internal channels. However, regardless of the origin, that massive amount of PharmaCyte data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of PharmaCyte Biotech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of PharmaCyte Biotech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to PharmaCyte Biotech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive PharmaCyte Biotech alpha.
PharmaCyte Largest EPS Surprises
Earnings surprises can significantly impact PharmaCyte Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-03-15 | 2022-01-31 | -0.05 | -0.04 | 0.01 | 20 | ||
2021-12-14 | 2021-10-31 | -0.07 | -0.06 | 0.01 | 14 | ||
2022-12-14 | 2022-10-31 | -0.08 | -0.0914 | -0.0114 | 14 | ||
2022-07-28 | 2022-04-30 | -0.04 | -0.07 | -0.03 | 75 | ||
2023-03-16 | 2023-01-31 | -0.08 | -0.0402 | 0.0398 | 49 | ||
2023-07-31 | 2023-04-30 | -0.09 | -0.0075 | 0.0825 | 91 |
PharmaCyte Biotech Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to PharmaCyte Biotech Stock. The global stock market is bearish. About 60% of major world exchanges and indexes are down. See today's market update for more information.
19th of April 2024
Life Science Cares Launches in Switzerland at globenewswire.com
19th of April 2024
Prosecutor wont bring charges against Wisconsin lawmaker over fundraising scheme at aol.com
18th of April 2024
Former Wisconsin Democratic Rep. Peter Barca announces new bid for Congress at ajc.com
17th of April 2024
Will Champions Oncology Spend Its Cash Wisely at finance.yahoo.com
17th of April 2024
Connect Biopharma shares target raised on strategic focus at investing.com
16th of April 2024
Pharvaris Price Target Cut to 34.00 - Defense World at news.google.com
15th of April 2024
Invivyd Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.... at benzinga.com
15th of April 2024
Hochul to announce preliminary agreement on state budget at nypost.com
12th of April 2024
Invivyd names Jeremy Gowler as interim CEO at investing.com
11th of April 2024
PharmaCyte Biotech Announces Closing of 70 Million Registered Direct Offering Priced At-th... at news.google.com
11th of April 2024
Eliem Therapeutics to acquire Tenet Medicines for autoimmune focus at investing.com
11th of April 2024
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Ex... at finance.yahoo.com
11th of April 2024
Insider Trading at MacroaxisInsider
10th of April 2024
Pharvaris reports Q4 results at seekingalpha.com
9th of April 2024
Ovid Therapeutics Data Readouts For Rare Epileptic Indications Late 2024 - Seeking Alpha at news.google.com
9th of April 2024
DFDS UDVIDER LOGISTIKNETVRK TIL TYRKIET at globenewswire.com
8th of April 2024
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635 at finance.yahoo.com
8th of April 2024
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy ... at benzinga.com
8th of April 2024
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024 at finance.yahoo.com
8th of April 2024
Water charges John ODowd rules out NI Water mutualisation at finance.yahoo.com
5th of April 2024
BMO maintains Outperform rating on Y-mAbs stock at investing.com
5th of April 2024
ELYM Stock Earnings Eliem Therapeutics Reported Results for Q4 2023 at investorplace.com
4th of April 2024
Invivyd Provides PEMGARDALaunch Update and Announces 2024 Net Product Revenue Guidance in ... at finance.yahoo.com
4th of April 2024
NextCure adds oncology expert to advisory board at investing.com
2nd of April 2024
AN2 Therapeutics stock upgraded by JPM Securities on drug path clarity at investing.com
1st of April 2024
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare C... at benzinga.com
1st of April 2024
Acquisition by Brady Davis of 135000 shares of Champions Oncology at 6.5 subject to Rule 1... at news.google.com
28th of March 2024
Disposition of 300000 shares by Henig Noreen of Kezar Life at 4.56 subject to Rule 16b-3 at MacroaxisInsider
27th of March 2024
PharmaCyte Biotech Stock Price Down 1.6 percent - Defense World at news.google.com
26th of March 2024
Nuvation Bio shares upgraded on promising drug prospects at investing.com
25th of March 2024
ONGOING INVESTIGATION ALERT The Schall Law Firm Announces it is Investigating Claims Again... at accesswire.com
22nd of March 2024
Ovid Therapeutics Reaches US197m Market Cap Benefiting Insider Stock Buying at finance.yahoo.com
22nd of March 2024
NXTC Stock Earnings NextCure Beats EPS for Q4 2023 at investorplace.com
22nd of March 2024
TIL Stock Earnings Instil Bio Beats EPS for Q4 2023 at investorplace.com
21st of March 2024
MLYS Stock Earnings Mineralys Therapeutics Beats EPS for Q4 2023 at investorplace.com
21st of March 2024
NextCure Provides Business Update and Reports Full Year 2023 Financial Results at globenewswire.com
20th of March 2024
Factbox-Biggest cyberattacks in US healthcare sector at finance.yahoo.com
19th of March 2024
PMCB Stock Earnings PharmaCyte Biotech Reported Results for Q3 2024 at investorplace.com
19th of March 2024
Disposition of 593000 shares by Novo Holdings As of Spruce BiosciencesInc at 0.755 subject... at investing.com
19th of March 2024
Champions Oncology, Inc. Q3 2024 Earnings Call Transcript at insidermonkey.com
19th of March 2024
Connect Biopharma to Participate in H.C. Wainwright 2 Annual Autoimmune Inflammatory Disea... at benzinga.com
19th of March 2024
Disposition of 5082333 shares by Curative Ventures V Llc of Instil Bio subject to Rule 16b... at MacroaxisInsider
14th of March 2024
IPSC Stock Earnings Century Therapeutics Misses EPS, Misses Revenue for Q4 2023 at investorplace.com
14th of March 2024
Nuvation Bio Doses First Patient in Phase 12 Study of NUV-1511 for the Treatment of Advanc... at businesswire.com
12th of March 2024
Champions Oncology Reports Quarterly Revenue of 12.0 Million at accesswire.com
12th of March 2024
SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 The... at prnewswire.com
11th of March 2024
Is Y-mAbs Therapeutics Inc a Leader in the Biotechnology Industry - InvestorsObserver at news.google.com
8th of March 2024
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635 at businesswire.com
8th of March 2024
Ovid Therapeutics GAAP EPS of -0.22 misses by 0.19, revenue of 0.14M at seekingalpha.com
6th of March 2024
Y-mAbs Therapeutics Shares Up 8.2 percent Following Analyst Upgrade at thelincolnianonline.com
6th of March 2024
Acquisition by Sasser Amy Kate of 33409 shares of Shattuck LabsInc at 9.47 subject to Rule... at MacroaxisInsider
6th of March 2024
Century Therapeutics Will Have To Spend Its Cash Wisely at simplywall.st
5th of March 2024
Levi Korsinsky, LLP Investigates Possible Securities Fraud Violations by AN2 Therapeutics,... at accesswire.com
1st of March 2024
Molecular Partners Announces Dismissal of Class Action Lawsuit at benzinga.com
15th of February 2024
Acquisition by Jon Congleton of 425000 shares of Mineralys Therapeutics subject to Rule 16... at MacroaxisInsider
15th of February 2024
Short Interest in Connect Biopharma Holdings Limited Grows By 52.8 percent - AmericanBanki... at news.google.com
14th of February 2024
Should You Hold PepGen Inc in Biotechnology Industry - InvestorsObserver at news.google.com
14th of February 2024
Instil Bio Executives Secure Retention Bonus Agreements - TipRanks at news.google.com
13th of February 2024
Shattuck Strikes Joint Development Deal With Japans Ono Pharma at marketwatch.com
13th of February 2024
Short Interest in Graphite Bio, Inc. Decreases By 31.5 percent - MarketBeat at news.google.com
8th of February 2024
Mineralys Therapeutics secures 120 million in private financing at investing.com
7th of February 2024
PepGen Announces Pricing of 80.1 Million Underwritten Offering of Common Stock at finance.yahoo.com
6th of February 2024
Kalamazoo set to net 33m from Ashburton project sale at thewest.com.au
2nd of February 2024
Eliem Therapeutics Shares Up 3.5 percent - MarketBeat at news.google.com
19th of January 2024
Icosavax shares tick lower as HSR filing for AstraZeneca deal withdrawn, refiled - Seeking... at news.google.com
2nd of January 2024
Guggenheim Downgrades Icosavax Inc. to Neutral at streetinsider.com
14th of December 2023
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split - GlobeNewswire at news.google.com
13th of December 2023
Icosavax, Inc. Is Up 0.10 percent in One Week What You Should Know at finance.yahoo.com
28th of August 2023
MediPacific Offering 2.13 Per Share Plus One Contingent Value Right Per Share in Tender Of... at finance.yahoo.com
1st of August 2023
SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates NEWR, AEL, PRDS at hawaiinewsnow.com
19th of July 2023
SHAREHOLDER ACTION ALERT The Schall Law Firm Announces it is Investigating Claims Against ... at accesswire.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards PharmaCyte Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, PharmaCyte Biotech's short interest history, or implied volatility extrapolated from PharmaCyte Biotech options trading.
Check out PharmaCyte Biotech Backtesting and PharmaCyte Biotech Hype Analysis. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.Note that the PharmaCyte Biotech information on this page should be used as a complementary analysis to other PharmaCyte Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for PharmaCyte Stock analysis
When running PharmaCyte Biotech's price analysis, check to measure PharmaCyte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaCyte Biotech is operating at the current time. Most of PharmaCyte Biotech's value examination focuses on studying past and present price action to predict the probability of PharmaCyte Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaCyte Biotech's price. Additionally, you may evaluate how the addition of PharmaCyte Biotech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is PharmaCyte Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. If investors know PharmaCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PharmaCyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Return On Assets (0.05) | Return On Equity (0.02) |
The market value of PharmaCyte Biotech is measured differently than its book value, which is the value of PharmaCyte that is recorded on the company's balance sheet. Investors also form their own opinion of PharmaCyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is PharmaCyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PharmaCyte Biotech's market value can be influenced by many factors that don't directly affect PharmaCyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PharmaCyte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PharmaCyte Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PharmaCyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.